glp-1 receptor agonists show promise in treating substance use disorders Comparing Ozempic, Wegovy and Other
Description
N Engl J Med 2025
3) missing outcome data
This rapid increase in prescription rates followed the recent approval of two GLP-1R agonists, semaglutide (Ozempic, Wegovy) and liraglutide (Victoza), for weight management in obese or overweight patients
UCP2 mRNA expression increased after 24 hours of GLP-1 incubation [181]
